FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2510102579> ?p ?o ?g. }

• W2510102579 endingPage "61" @default.
• W2510102579 startingPage "61" @default.
• W2510102579 abstract "Objective. To study the opportunities to increase the efficiency of pathogenetic therapy in patients with chronic cerebrovascular diseases (CVD) (discirculatory encephalopathy, DE) on the background of metabolic syndrome (MS) using the drug Vitaxon®. The feature of the work was to identify strategic areas of the brain in cognitive and emotional disorders in patients with MS and its absence. Materials and methods. We observed 49 patients with DE II degree aged 37 to 73 years against the background of MS. The main group — 30 patients — received Vitaxon® as a part of treatment. The control group consisted of 19 patients with DE degree II following MS, comparable in the age and stage of the disease, who were not taking Vitaxon®. Patients were observed for 12 weeks. In addition to neurological, general clinical examinations, detection of MS signs, we have used neuropsychological tests by Mini Mental State Examination (MMSE) and Montreal Cognitive Assessment (МоСА), Spielberger anxiety scale; Beck depression scale; study of attention: search of numbers by Schulte tables with the assessment of task-performance time. The brain and its liquor system in 41 patients (27 patients with MS — the first group and 14 patients without MS — the second group) were evaluated using the method of volumetry (measuring the volume of certain brain regions), on the magnetic resonance imaging scanner Toshiba Vantage Titan 1.5. Results. Cognitive impairment in both groups manifested by the loss of memory, attention disorders, slowing of mental processes. After 12 weeks, the median by the MMSE significantly increased by 3.3 % (p < 0.05 compared with the first test) in patients who received Vitaxon®. By МоСА, which is more sensitive when determining the mild cognitive impairment, in a group of Vitaxon® cognitive functions improved by 5 %, while in the control group — by 1.66 %. By Spielberger scale, state anxiety indicators improved more in the group of patients who received study drug: at baseline — 42.4 ± 3.4 points and 24.6 ± 2.8 points at week 12 (p < 0.05). It was determined that cognitive performance by МоСА scale was inversely dependent on the parameters of glycated hemoglobin. Results of volumetric studies showed significant (p < 0.05) reduction in the volume of the brain substance, cortex and the volume of white matter of the cerebral hemispheres, temporal lobe in patients with CVD on the background of MS compared with those of similar age with no signs of MS. In addition, patients with MS had the likely decrease in the area of the corpus callosum (p < 0.05) compared to patients without MS. Conclusions. During the treatment of patients with CVD following MS, it is necessary to consider anxiety-asthenic conditions and cognitive disorders that often occur at this pathology. Addition of Vitaxon® to the generally accepted drug therapy helps to eliminate psycho-emotional disorders. In patients with chronic CVD on the background of MS, the degree of the atrophy of the cortex and white matter of the cerebral hemispheres, the frontal and temporal lobes, as well as the corpus callosum, was significantly higher (p < 0.05) compared to patients without MS." @default.
• W2510102579 created "2016-09-16" @default.
• W2510102579 creator A5060801637 @default.
• W2510102579 date "2015-03-15" @default.
• W2510102579 modified "2023-10-16" @default.
• W2510102579 title "Pathogenetic Aspects of Preventive Correction of Cognitive Impairment in Metabolic Syndrome" @default.
• W2510102579 cites W1896317507 @default.
• W2510102579 cites W2036174860 @default.
• W2510102579 cites W2055655339 @default.
• W2510102579 cites W2066429484 @default.
• W2510102579 cites W2074249519 @default.
• W2510102579 cites W2077474227 @default.
• W2510102579 cites W2117579257 @default.
• W2510102579 cites W2140174229 @default.
• W2510102579 cites W2145451941 @default.
• W2510102579 cites W2171969403 @default.
• W2510102579 doi "https://doi.org/10.22141/2224-0721.1.73.2016.71069" @default.
• W2510102579 hasPublicationYear "2015" @default.
• W2510102579 type Work @default.
• W2510102579 sameAs 2510102579 @default.
• W2510102579 citedByCount "0" @default.
• W2510102579 crossrefType "journal-article" @default.
• W2510102579 hasAuthorship W2510102579A5060801637 @default.
• W2510102579 hasBestOaLocation W25101025791 @default.
• W2510102579 hasConcept C118552586 @default.
• W2510102579 hasConcept C126322002 @default.
• W2510102579 hasConcept C139719470 @default.
• W2510102579 hasConcept C14216870 @default.
• W2510102579 hasConcept C162324750 @default.
• W2510102579 hasConcept C169900460 @default.
• W2510102579 hasConcept C187212893 @default.
• W2510102579 hasConcept C2776867660 @default.
• W2510102579 hasConcept C2779631380 @default.
• W2510102579 hasConcept C2984915365 @default.
• W2510102579 hasConcept C558461103 @default.
• W2510102579 hasConcept C71924100 @default.
• W2510102579 hasConceptScore W2510102579C118552586 @default.
• W2510102579 hasConceptScore W2510102579C126322002 @default.
• W2510102579 hasConceptScore W2510102579C139719470 @default.
• W2510102579 hasConceptScore W2510102579C14216870 @default.
• W2510102579 hasConceptScore W2510102579C162324750 @default.
• W2510102579 hasConceptScore W2510102579C169900460 @default.
• W2510102579 hasConceptScore W2510102579C187212893 @default.
• W2510102579 hasConceptScore W2510102579C2776867660 @default.
• W2510102579 hasConceptScore W2510102579C2779631380 @default.
• W2510102579 hasConceptScore W2510102579C2984915365 @default.
• W2510102579 hasConceptScore W2510102579C558461103 @default.
• W2510102579 hasConceptScore W2510102579C71924100 @default.
• W2510102579 hasIssue "1.73" @default.
• W2510102579 hasLocation W25101025791 @default.
• W2510102579 hasLocation W25101025792 @default.
• W2510102579 hasOpenAccess W2510102579 @default.
• W2510102579 hasPrimaryLocation W25101025791 @default.
• W2510102579 hasRelatedWork W1981279109 @default.
• W2510102579 hasRelatedWork W2055669556 @default.
• W2510102579 hasRelatedWork W2097112701 @default.
• W2510102579 hasRelatedWork W2230907131 @default.
• W2510102579 hasRelatedWork W2591620179 @default.
• W2510102579 hasRelatedWork W2767002755 @default.
• W2510102579 hasRelatedWork W2769600044 @default.
• W2510102579 hasRelatedWork W2967155456 @default.
• W2510102579 hasRelatedWork W4200118627 @default.
• W2510102579 hasRelatedWork W4313173265 @default.
• W2510102579 hasVolume "0" @default.
• W2510102579 isParatext "false" @default.
• W2510102579 isRetracted "false" @default.
• W2510102579 magId "2510102579" @default.
• W2510102579 workType "article" @default.